AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00544596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01279824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention
Study NCT01279824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention
Study NCT01279824 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: swallowing therapy
Description: Standardized behavioral swallowing intervention
Study NCT00439985 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
Study NCT04319471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/S-1
Description: Drug: Capecitabine/S-1
Study NCT04319471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
Study NCT04319471 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Head and neck radiotherapy
Description: IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
Study NCT04319471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Consolidative Therapy
Description: radiotherapy，surgery or interventional therapy for all metastatic sites.
Study NCT00544596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00259857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
Study NCT04450316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab nightly
Study NCT02496442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueduct
Description: Using Aqueduct in procedures to continuously supply the irrigation solutions
Study NCT00259857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate
Description: Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
Study NCT03704181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG twice day for one year
Description: placebo twice day for one year
Study NCT03704181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo twice day for one year
Study NCT04406805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of plasma and urine trimethylamine-N-oxide concentration
Description: Information already included in arm/group descriptions.
Study NCT01527786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: 50mg-100mg everyday for 12 weeks over 7 study visits
Study NCT04045665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet-only strategy
Description: Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study NCT04045665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Anticoagulant plus background antiplatelet therapy
Description: OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
Study NCT03958877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a)
Description: Administered as specified in the treatment arm
Study NCT03958877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta type 1a
Description: Administered as specified in the treatment arm
Study NCT04990726 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Undergo medical assessments
Study NCT04990726 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04990726 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04990726 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03518320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Description: TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Study NCT03518320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
Study NCT01785602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: Capsules
Study NCT00461396 — intervention group
Intervention type: DRUG
Intervention: Interferon-1beta (Betaseron, BAY86-5046)
Description: Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
Study NCT02251431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYDUREON
Description: Exenatide-extended release, Cohorts A and B
Study NCT02251431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort A only
Study NCT01136941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
Study NCT01785602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT03811366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid monotherapy
Description: Patients will receive corticosteroid monotherapy as a pulsetherapy (1000mg/ day for 3 days) followed by oral corticosteroid.
Study NCT02143479 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study NCT03694483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis for the detection of prostasomes
Description: Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing.
Study NCT04141761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: This group will receive Visbiome probiotic in powder form.
Study NCT04141761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a placebo in powder form.
Study NCT01246102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
Study NCT00003861 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT02928991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for Acquired AA
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0
Study NCT02928991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0
Study NCT06155617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Upper Extremity Rehabilitation
Description: Pain management, ROM, Edema Management, Desensitization, Strengthening, Functional Tasks
Study NCT02526992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HR-pQCT
Description: HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
Study NCT02928991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
Description: Fludarabine: Dose: 30mg/m2/day (\<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)\*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0
Study NCT03026894 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Panoramic Radiograph
Description: Measurement of bone resorption
Study NCT03026894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan III occlusal system
Description: Recording percentage of force in maximum intercuspation
Study NCT01849029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Cognitive
Description: Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
Study NCT01849029 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Processing Therapy-Cognitive
Description: Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
Study NCT03630926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NV-VPAC1 PCa Urine Diagnostic Test
Description: The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
Study NCT06244329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.
Study NCT04466280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg of hydroxychloroquine daily for participants in the intervention group 1
Study NCT04466280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucodentol
Description: Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
Study NCT04466280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal protective equipment
Description: Personal protective equipment such as masks, gloves, protective shields
Study NCT04466280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal protective equipment
Description: Personal protective equipment such as masks, gloves, protective shields
Study NCT03214224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT03214224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study NCT03957044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The education of sensory integration with vestibular education
Description: Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used.
Study NCT03509064 — intervention group
Intervention type: OTHER
Intervention: Collection sheet
Description: Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
Study NCT03076892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aktilite® Galderma
Description: preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
Study NCT03076892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOS ISTOS PDT
Description: preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
Study NCT03630497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration
Study NCT04560712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture
Study NCT04560712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo usual care
Study NCT04560712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care
Study NCT04560712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04560712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03183791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAXaHEAD app
Description: The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
Study NCT03183791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app.
Study NCT04471584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of ILR device
Description: All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
Study NCT01403103 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study NCT01403103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01403103 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study NCT01403103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01403103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01403103 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT04354922 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise intervention
Description: Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
Study NCT04354922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise intervention
Description: Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.
Study NCT02949219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02949219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01806259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IV
Description: Active drug
Study NCT02459691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vida Sana
Description: Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.